Experience with early treatment using febuxostat in a patient with adenine phosphoribosyltransferase deficiency after pediatric kidney transplantation: a case report.

CEN Case RepSep 2, 2026 (epub)
Case ReportNephrologyPediatricsOpen access

Yujiro Aoki, Maho Maeda, Junya Hashimoto et al.

✦ AI-curated · Sources linked

Case in brief

A 12-year-old boy with adenine phosphoribosyltransferase (APRT) deficiency underwent kidney transplantation after experiencing acute kidney injury and requiring peritoneal dialysis. He had a history of urinary tract stones and recurrent infections, leading to surgical interventions. Post-transplant, his treatment was switched from allopurinol to febuxostat, with stable graft function and no recurrence of dihydroxyadenine nephropathy observed at four months.

Diagnostic / clinical pearl

Febuxostat may be a viable alternative to allopurinol for managing APRT deficiency in pediatric kidney transplant patients, particularly when allopurinol is ineffective.

Source

PubMed · PMID 42684660Free full text on PubMed Central

Published in CEN Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.